Sponsor or institution

Clinical trials and research at Revolution Medicines, Inc.

• 13Clinical trials
• 25Countries

Newest trials

All recruiting trials (13)

• Zoldonrasib plus Daraxonrasib vs Gemcitabine and Nab-Paclitaxel as first-line treatment for metastatic KRAS G12D pancreatic cancer

  This study tests whether two investigational RAS inhibitors together can improve outcomes compared with standard chemotherapy in adults with newly diagnosed metastatic pancreatic cancer carrying the KRAS G12D mutation.

  Recruiting at 6 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 5 other locations · NCT07805954

• First-line treatment with pembrolizumab, pemetrexed, and platinum with or without zoldonrasib for metastatic non-squamous NSCLC

  This trial tests whether adding zoldonrasib to standard pembrolizumab and platinum chemotherapy helps people with untreated metastatic non-squamous NSCLC that has a RAS G12D mutation.

  Recruiting at 4 sites Phase 3 Revolution Medicines, Inc. · Anchorage, Alaska and 3 other locations · NCT07777822

• Zoldonrasib + chemotherapy vs placebo + chemotherapy as first-line treatment for metastatic KRAS G12D pancreatic cancer

  This trial tests whether adding zoldonrasib to standard chemotherapy helps people with newly diagnosed metastatic KRAS G12D pancreatic cancer.

  Recruiting at 25 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 24 other locations · NCT07621718

• Daraxonrasib alone or with gemcitabine and nab-paclitaxel for first-line metastatic pancreatic cancer

  This trial will see if daraxonrasib, alone or with gemcitabine and nab-paclitaxel, helps people with newly diagnosed metastatic pancreatic cancer live longer or slow tumor growth compared with standard gemcitabine and nab-paclitaxel.

  Recruiting at 61 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 81 other locations · NCT07491445

• Combining RAS(ON) inhibitors with ivonescimab for adults with RAS‑mutant advanced solid tumors

  This trial will test whether combining RAS(ON) inhibitors with ivonescimab is safe and can shrink or control tumors in adults with advanced or metastatic solid tumors that have RAS mutations.

  Recruiting at 19 sites Phase 1/2 Revolution Medicines, Inc. · Scottsdale, Arizona and 18 other locations · NCT07397338

• RMC-5127 for advanced cancers with KRAS G12V mutation

  This trial will test whether the experimental drug RMC-5127, alone or with daraxonrasib or cetuximab, helps adults with advanced KRAS G12V-mutant solid tumors.

  Recruiting at 9 sites Phase 1 Revolution Medicines, Inc. · New Haven, Connecticut and 8 other locations · NCT07349537

• Daraxonrasib after surgery for resected pancreatic ductal adenocarcinoma (PDAC)

  This trial tests whether taking daraxonrasib after surgery can help prevent cancer from coming back in adults with resected PDAC who completed perioperative chemotherapy.

  Recruiting at 85 sites Phase 3 Revolution Medicines, Inc. · Birmingham, Alabama and 85 other locations · NCT07252232

• Evaluating daraxonrasib for previously treated patients with RAS mutated lung cancer

  This study is testing if a new drug called daraxonrasib can help people with RAS mutated lung cancer live longer and feel better compared to standard chemotherapy.

  Recruiting at 26 sites Phase 3 Revolution Medicines, Inc. · Birmingham, Alabama and 198 other locations · NCT06881784

• Evaluating RAS(ON) Inhibitors for Gastrointestinal Solid Tumors

  This study is testing new RAS(ON) inhibitors combined with standard treatments to see if they can help people with certain types of gastrointestinal cancers that have RAS mutations.

  Recruiting at 32 sites Phase 1/2 Revolution Medicines, Inc. · Chandler, Arizona and 31 other locations · NCT06445062

• Evaluating RAS inhibitors for advanced lung cancer

  This study is testing new RAS inhibitors combined with standard treatments to see if they can help people with advanced lung cancer that has specific RAS mutations.

  Recruiting at 53 sites Phase 1/2 Revolution Medicines, Inc. · Gilbert, Arizona and 97 other locations · NCT06162221

• Evaluating RMC-6291 and RMC-6236 for Advanced KRAS G12C Mutant Solid Tumors

  This study is testing a new combination of drugs to see if they can safely help adults with advanced solid tumors that have a specific KRAS mutation.

  Recruiting at 52 sites Phase 1/2 Revolution Medicines, Inc. · Duarte, California and 55 other locations · NCT06128551

• Evaluating RMC-9805 for KRAS G12D-Mutant Solid Tumors

  This study is testing a new drug called RMC-9805 to see if it can safely help adults with solid tumors that have a specific KRAS G12D mutation.

  Recruiting at 17 sites Phase 1 Revolution Medicines, Inc. · Sacramento, California and 16 other locations · NCT06040541

• Evaluating RMC-6236 for advanced solid tumors with specific RAS mutations

  This study is testing a new drug called RMC-6236 to see if it can help adults with advanced solid tumors that have certain RAS mutations.

  Recruiting at 21 sites Phase 1/2 Revolution Medicines, Inc. · Orange, California and 20 other locations · NCT05379985

Quick answers

How many clinical trials run by Revolution Medicines, Inc. are recruiting right now?

13, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 25 countries. The most sites are in United States (13 trials), Italy (6 trials), Germany (5 trials), Netherlands (5 trials), Spain (5 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 6, Phase 1/2: 5, Phase 1: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →